- Fulcrum Therapeutics ( NASDAQ: FULC ) on Monday said its chief medical officer Christopher Morabito will be leaving the company effective July 13.
- FULC said its R&D president Judith Dunn will be the interim chief medical officer while the company searches for a new executive.
- FULC said Dunn had assumed direct oversight of all clinical activities and related functions.
- Prior to joining Fulcrum ( FULC ), Dunn had held multiple leadership positions including leading global clinical development for Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ).
- FULC stock earlier closed -4.1% at $5.69.
For further details see:
Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave